Skip to main content

Table 3 NSABP FB-7: Pathologic complete response (pCR) (breast and nodes) by treatment arm and HR status

From: Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer

Treatment arms,
n = 42 each arm
Total pCRP-value for pCR T vs Other Arms in all patientsapCR HR+P-value for pCR T vs Other Arms in HR+ bpCR HRP-value for pCR T vs Other Arms in HR− bP-value HR+ vs HR
Arm 1 (T)16/41 (39.0%)NA8/27 (29.6%)NA8/14 (57.1%)NA0.11
Arm 2 (N)14/42 (33.3%)0.638/29 (27.6%)16/13 (46.2%)0.710.30
Arm 3 (T plus N)21/42 (50%)0.227/23 (30.4%)114/19 (73.7%)0.460.01
All arms51/126 (40%) 23/79 (29%) 28/46 (61%) 0.001
  1. Abbreviations: T, trastuzumab; N, neratinib
  2. aCMH test stratified for the time period the patients were randomized to the study (prior/after the addition of Arm 3)
  3. bFisher’s exact test